Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer
NCT06417476Phase 2Active, not recruiting
- Start
- Dec 2022
- Primary completion
- Sep 2025
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, oxaliplatin, folinic acid, fluorouracil in rectal cancer. Started Dec 2022; status: active, not recruiting.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatinfolinic acidfluorouracil
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06417476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06417476.